Drug Profile
Anti-EPCAM CAR T-cell therapy - Sinobioway Cell Therapy
Alternative Names: CAR T-cell therapy - Sinobioway Cell Therapy; CAR-T EPCAM therapy; Chimeric antigen T-cell therapies - Sinobioway Cell TherapyLatest Information Update: 22 Oct 2020
Price :
$50
*
At a glance
- Originator Sinobioway Cell Therapy
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer; Liver cancer
Most Recent Events
- 22 Oct 2020 No development reported - Phase-I/II for Gastric cancer (Late-stage disease) in China (IV)
- 22 Oct 2020 No development reported - Phase-II for Liver cancer (In adolescents, In children, In the elderly, Late-stage disease, Refractory metastatic disease, In adults) in China (IV)
- 21 Mar 2017 Sinobioway Cell Therapy resumes patient enrolment in a phase I/II trial for Gastric cancer (Late-stage disease) in China (NCT02725125)